Comparison of Blood Collection Tubes from Three Different Manufacturers for the Collection of Cell-Free DNA for Liquid Biopsy Mutation Testing

被引:63
作者
Alidousty, Christina [1 ]
Brandes, Danielle [1 ]
Heydt, Carina [1 ]
Wagener, Svenja [1 ]
Wittersheim, Maike [1 ]
Schaefer, Stephan C. [1 ]
Holz, Barbara [1 ]
Merkelbach-Bruse, Sabine [1 ]
Buettner, Reinhard [1 ]
Fassunke, Jana [1 ]
Schultheis, Anne M. [1 ]
机构
[1] Univ Hosp Cologne, Inst Pathol, Cologne, Germany
关键词
CIRCULATING TUMOR DNA; CANCER-PATIENTS; LUNG-CANCER; PLASMA; EGFR; RESISTANCE;
D O I
10.1016/j.jmoldx.2017.06.004
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The improvement in sensitive techniques has allowed the detection of tumor-specific aberrations in circulating tumor (ct) DNA. Amplification-refractory mutation system PCR has been used for the analysis of ctDNA to detect resistance-causing mutations in the epidermal growth factor receptor gene (eg, EGFR T790M) in lung cancer patients. So far, Streck tubes have been widely used as standard blood collection tubes. Here, we compared blood collection tubes manufactured by Streck with tubes from Roche and Qiagen regarding their utility in stabilizing ctDNA in plasma samples. Venous blood from healthy donors was collected in tubes from Streck, Roche, and Qiagen. Samples were spiked with artificially fragmented EGFR T790M-mutated DNA and stored for different periods of time or spiked with different DNA amounts before plasma preparation. Extracted ctDNA was analyzed by amplification-refractory mutation system PCR. Mutant DNA, spiked into blood samples from healthy donors at quantities of 1 or 3 ng, was still reliably detectable in all samples after 7 days. EGFR T790M could be detected when spiking was performed with an amount of artificial ctDNA of 0.5 ng when tubes from Roche and Qiagen were used. Blood collection tubes from Roche and Qiagen are highly suitable for ctDNA stabilization and subsequent liquid biopsy testing. Even low ctDNA concentrations allow the detection of somatic mutations.
引用
收藏
页码:801 / 804
页数:4
相关论文
共 12 条
  • [1] Targeted therapy for non-small cell lung cancer: current standards and the promise of the future
    Chan, Bryan A.
    Hughes, Brett G. M.
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2015, 4 (01) : 36 - 54
  • [2] Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification
    Devonshire, Alison S.
    Whale, Alexandra S.
    Gutteridge, Alice
    Jones, Gerwyn
    Cowen, Simon
    Foy, Carole A.
    Huggett, Jim F.
    [J]. ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2014, 406 (26) : 6499 - 6512
  • [3] Liquid Biopsies: Genotyping Circulating Tumor DNA
    Diaz, Luis A.
    Bardelli, Alberto
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (06) : 579 - +
  • [4] Free Circulating Tumor DNA as a Diagnostic Marker for Breast Cancer
    Hashad, D.
    Sorour, A.
    Ghazal, A.
    Talaat, I.
    [J]. JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2012, 26 (06) : 467 - 472
  • [5] Mechanisms of resistance to EGFR tyrosine kinase inhibitors
    Huang, Lihua
    Fu, Liwu
    [J]. ACTA PHARMACEUTICA SINICA B, 2015, 5 (05) : 390 - 401
  • [6] Jahr S, 2001, CANCER RES, V61, P1659
  • [7] No JH, 2012, ANTICANCER RES, V32, P3467
  • [8] Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
    Pao, W
    Miller, VA
    Politi, KA
    Riely, GJ
    Somwar, R
    Zakowski, MF
    Kris, MG
    Varmus, H
    [J]. PLOS MEDICINE, 2005, 2 (03) : 225 - 235
  • [9] Quantitative analysis of cell-free DNA in the plasma of gastric cancer patients
    Park, Jong-Lyul
    Kim, Hyun Ja
    Choi, Bo Youl
    Lee, Han-Chul
    Jang, Hay-Ran
    Song, Kyu Sang
    Noh, Seung-Moo
    Kim, Seon-Young
    Han, Dong Soo
    Kim, Yong Sung
    [J]. ONCOLOGY LETTERS, 2012, 3 (04) : 921 - 926
  • [10] Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Reck, M.
    Popat, S.
    Reinmuth, N.
    De Ruysscher, D.
    Kerr, K. M.
    Peters, S.
    [J]. ANNALS OF ONCOLOGY, 2014, 25 : 27 - 39